Inhibitors of the thioredoxin redox system have been implicated in the inhibition of pro-angiogenic effectors, hypoxia-inducible factor-1 α (HIF1α) and vascular endothelial growth factor (VEGF), both of which are overexpressed in many malignancies including pancreatic cancer [18], [19], [20]. The gene discussed is VEGFA; the disease is pancreatic neoplasm.